Fabrizio, David
Foundation Medicine (United States)
6 papers on CoChatORCID 0000-0001-8088-9476
Most cited papers
- Verified
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine
Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics
Cited by 3,519
- Verified
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics
Cited by 2,552
- Verified
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 1,641
- Verified
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 481
- Verified
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Lee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., Ross, J. S., Frampton, G. M., Napalkov, P., Montesion, M., et al. (2022) · npj Precision Oncology
Cancer Genomics and DiagnosticsProtein Kinase Regulation and GTPase Signaling
Cited by 187
- Verified
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.
Subbiah, V., Khawaja, M. R., Hong, D. S., Amini, B., Yungfang, J., Liu, H., Johnson, A., Schrock, A. B., Ali, S. M., Sun, J. X., et al. (2017) · JCI Insight
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 30
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free